Last reviewed · How we verify
0.75% Ropivacaine
At a glance
| Generic name | 0.75% Ropivacaine |
|---|---|
| Also known as | Naropin |
| Sponsor | Northwestern University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- PUSHES (Pudendal Block Versus Sacral ESP Hemorrhoidectomy Study) (NA)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- EOIB for Pain After Laparoscopic Cholecystectomy (NA)
- External Oblique Intercostal Plane Block for Postoperative Analgesia After Major Upper Abdominal Surgery (NA)
- Cryoablation of Intercostal Nerves for Pain Management in Early Postoperative Period in Patients With Minimally Invasive Mitral Valve Surgery (NA)
- Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy (PHASE4)
- A Multidisciplinary Perioperative Pain Management (NA)
- Postoperative Experience of 2 WALANT-type Modes of Anesthesia Used in Ambulatory Surgery of the Upper Limb. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 0.75% Ropivacaine CI brief — competitive landscape report
- 0.75% Ropivacaine updates RSS · CI watch RSS
- Northwestern University portfolio CI